Inion receives Patent Grant for Biotech Application of a Genetically Modified Variant of Bone Morphogenetic Protein

First biotech patent resulting from programme to develop next-generation bioactive biomaterials

04-Apr-2006

Inion announced the granting of a patent covering a genetically modified form of the bone morphogenetic protein BMP-4, which prevents the abnormal formation of bone in extra-skeletal tissues. This patent (No. 116827) has been granted in Finland and is issued in the US. Bone morphogenetic proteins (BMPs) are used to supplement bone graft material in many orthopaedic procedures, notably spinal fusions. The advantages are that BMPs promote bone growth and thus enhance and accelerate fusion.

This novel form of BMP, now patented by Inion, has the potential to be developed into a biological treatment modality for the treatment of a condition known as heterotopic ossification (HO), wherein bone forms spontaneously in non-bony tissues e.g. muscles. HO is observed in up to 50% of patients receiving spinal fusion surgery and as much as 71% of patients receiving total hip replacements.

Inion is exploring routes to market for this novel form of BMP, which may involve an out-licensing agreement to commercialise this intellectual property with an appropriate partner. According to Inion, there is significant market potential for a product that reduces the incidence of HO in a more cost-effective form.

Research on variant forms of BMP and their potential use in conjunction with Inion's biodegradable medical implants is being conducted at Inion's European Technical Centre in Cambridge, UK, as part of the Company's strategy to develop third-generation bioactive and biodegradable materials platforms.

https://www.bionity.com/en/news/53677/inion-receives-patent-grant-for-biotech-application-of-a-genetically-modified-variant-of-bone-morphogenetic-protein.html